Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University School of Medicine, Taoyuan, Taiwan.
State Key Lab of Molecular Oncology, Laboratory of Cell and Molecular Biology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
J Pathol. 2019 May;248(1):41-50. doi: 10.1002/path.5219. Epub 2019 Feb 15.
The clonal relationship between ovarian high-grade serous carcinoma (HGSC) and its presumed precursor lesion, serous tubal intraepithelial carcinoma (STIC), has been reported. However, when analyzing patients with concurrent ovarian carcinoma and tubal lesion, the extensive carcinoma tissues present at diagnosis may have effaced the natural habitat of precursor clone(s), obscuring tumor clonal evolutionary history, or may have disseminated to anatomically adjacent fimbriae ends, masquerading as precursor lesions. To circumvent these limitations, we analyzed the genomic landscape of incidental tubal precursor lesions including p53 signature, dormant STIC or serous tubal intraepithelial lesion (STIL) and proliferative STIC in women without ovarian carcinoma or any cancer diagnosis using whole-exome sequencing and amplicon sequencing. In three of the four cancer-free women with multiple discrete tubal lesions we observed non-identical TP53 mutations between precursor lesions from the same individual. In one of the four women with co-existing ovarian HGSC and tubal precursor lesion we found non-identical TP53 mutations and a lack of common mutations shared between her precursor lesion and carcinoma. Analyzing the evolutionary history of multiple tubal lesions in the same four patients with concurrent ovarian carcinoma indicated distinct evolution trajectories. Collectively, the results support diverse clonal origins of tubal precursor lesions at the very early stages of tumorigenesis. Mathematical modeling based on lesion-specific proliferation rates indicated that p53 signature and dormant STIC may take a prolonged time (two decades or more) to develop into STIC, whereas STIC may progress to carcinoma in a much shorter time (6 years). The above findings may have implications for future research aimed at prevention and early detection of ovarian cancer. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
卵巢高级别浆液性癌 (HGSC) 与其假定的前体病变——输卵管上皮内癌 (STIC) 之间的克隆关系已被报道。然而,在分析同时患有卵巢癌和输卵管病变的患者时,广泛的癌组织在诊断时可能已经掩盖了前体克隆 (s) 的自然栖息地,使肿瘤克隆进化史变得模糊不清,或者可能已经扩散到解剖上相邻的输卵管末端,伪装成前体病变。为了规避这些限制,我们使用全外显子组测序和扩增子测序分析了无卵巢癌或任何癌症诊断的女性中偶然的输卵管前体病变的基因组景观,包括 p53 特征、休眠 STIC 或浆液性输卵管上皮内病变 (STIL) 和增生性 STIC。在四名无癌且有多个离散输卵管病变的女性中,我们观察到来自同一患者的前体病变之间存在非同源 TP53 突变。在四名同时患有卵巢 HGSC 和输卵管前体病变的女性中,我们发现非同源 TP53 突变,以及她的前体病变和癌之间缺乏共同突变。对同时患有卵巢癌的四名患者的多个输卵管病变的进化史进行分析表明,它们具有不同的进化轨迹。总的来说,这些结果支持在肿瘤发生的早期阶段,输卵管前体病变具有不同的克隆起源。基于病变特异性增殖率的数学模型表明,p53 特征和休眠 STIC 可能需要很长时间(二十年或更长时间)才能发展成 STIC,而 STIC 可能在更短的时间内(六年)进展为癌。这些发现可能对未来旨在预防和早期发现卵巢癌的研究具有重要意义。版权所有©2018 英国和爱尔兰病理学会。由 John Wiley & Sons, Ltd. 出版。